GSTM1 and coronary artery disorder: The best data among hemodialysis patients are from the Normal Hematocrit Trial (NHT), in which 1233 hemodialysis patients with cardiac disease, defined as heart failure or ischemic heart disease, and show that the group targeted to Hct 42 ± 3% (approximately Hb 14g/dl) had a higher risk of the combined endpoint of death or nonfatal myocardial infarction and the risk of thrombosis of grafts and fistulae comparing with Hct 30 ± 3% group (approximately Hb 10g/dl).